Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

1.565 +0.005 (+0.33%)
Streaming Delayed Price Updated: 3:43 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soligenix, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows. 
Via Benzinga
Recap: Soligenix Q4 Earnings
  Soligenix (NASDAQ:SNGX) reported its Q4 earnings results on Tuesday, March 29, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Soligenix, Inc. (NASDAQ: SNGX) Developing Treatments for Multiple Cancers, Vaccine Candidates (Ebola, Sudan, & Marburg)
Via Get News
Developing Treatments for Multiple Cancers; Vaccine Candidates (Ebola, Sudan, and Marburg) Plus a Novel Heat Stable COVID-19 & Ricin Toxin Vaccines: Soligenix, Inc. (NASDAQ: SNGX)
Via Viz Release
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 153 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 31.0% to $1.31 during Thursday's pre-market session. The company's market cap stands at $36.7 million.... 
Via Benzinga
Soligenix, Inc. (NASDAQ: SNGX) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Friday
On Friday, 213 companies hit new 52-week lows. 
Via Benzinga
Soligenix, Inc. (NASDAQ: SNGX) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
Via CryptoCurrencyWire
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... 
Via Benzinga
Soligenix Proof of Concept Uncovers Potential Treatment Option for the World's 125 Million Psoriasis Sufferers
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
56 Biggest Movers From Yesterday
Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating... 
Via Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary Pasithea Clinics has been approved to provide... 
Via Benzinga
21 Stocks Moving In Tuesday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 201% to $4.00 in pre-market trading. The company filed proxy statement for annual meeting after the market close on... 
Via Benzinga
Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022
In an SEC filing, Soligenix Inc (NASDAQ: SNGX) disclosed that it cannot file its HyBryte marketing application in the U.S. in 1H of 2022. Citing COVID-19 related... 
Via Benzinga
Topics Regulatory Compliance
30 Stocks Moving in Friday's Pre-Market Session
Gainers DBV Technologies S.A. (NASDAQ: DBVT) rose 20.3% to $3.68 in pre-market trading after declining 15% on Thursday. DBV Technologies, disclosed that on Oct. 14, it received... 
Via Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
18 Stocks Moving in Friday's Pre-Market Session
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) shares... 
Via Benzinga
Soligenix To Test Synthetic Hypericin In Psoriasis Patients
Soligenix Inc (NASDAQ: SNGX) says that following the validation of synthetic hypericin's biologic activity, the Company will be expanding the therapy under the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Xeris Pharmaceuticals (NASDAQ:XERS 
Via Benzinga
Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.